Headquartered in Switzerland and Boston, two global biotech-hubs, our ambition is to develop Spexis into a leading biopharmaceutical company with a strategic focus on rare diseases, oncology and antimicrobial resistance. With a strong scientific core, our drug discovery and research efforts are led by our in house scientist via leveraging our discovery platforms in collaboration with top academic centers around the globe. We have two clinical programs focused on products for rare, chronic respiratory diseases.
Spexis AG is a combination of the two legacy companies, Polyphor, a publicly listed Swiss biotech and EnBiotix, a privately held US biotech. In December 2021, two companies – Polyphor and EnBiotix – teamed up to join forces and formed Spexis.
Hegenheimermattweg 125, 4123 Allschwil – Switzerland
|Date||Trading entity / Person||Association||Trade type||Volume|
|21.06.22||None||Executive member||Other||CHF 0.00|
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.